Literature DB >> 30831072

Pharmacological effectors of GRP78 chaperone in cancers.

Christian Bailly1, Michael J Waring2.   

Abstract

The protein chaperone GRP78 is a master regulator of endoplasmic reticulum (ER) functions and is frequently over-expressed at the surface of cancer cells where it contributes to chemo-resistance. It represents a well-studied ER stress marker but an under-explored target for new drug development. This review aims to untangle the structural and functional diversity of GRP78 modulators, covering over 130 natural products, synthetic molecules, specific peptides and monoclonal antibodies that target GRP78. Several approaches to promote or to incapacitate GRP78 are presented, including the use of oligonucleotides and specific cell-delivery peptides often conjugated to cytotoxic payloads to design GRP78-targeted therapeutics. A repertoire of drugs that turn on/off GRP78 is exposed, including molecules which bind directly to GRP78, principally to its ATP site. There exist many options to regulate positively or negatively the expression of the chaperone, or to interfere with its cellular trafficking. This review provides a molecular cartography of GRP78 pharmacological effectors and adds weight to the notion that GRP78 repressors could represent promising anticancer therapeutics, notably as regards limiting chemo-resistance of cancer cells. The potential of GRP78-targeting drugs in other therapeutic modalities is also evoked.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticancer drugs; Cancer; Chaperone; GRP78; Monoclonal antibodies; Natural products

Year:  2019        PMID: 30831072     DOI: 10.1016/j.bcp.2019.02.038

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

1.  The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.

Authors:  Cheng-Wei Chou; Ri-Yao Yang; Li-Chuan Chan; Ching-Fei Li; Linlin Sun; Heng-Huan Lee; Pei-Chih Lee; Yuh-Pyng Sher; Haoqiang Ying; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 6.166

Review 2.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

3.  Canine osteosarcoma cells exhibit basal accumulation of multiple chaperone proteins and are sensitive to small molecule inhibitors of GRP78 and heat shock protein function.

Authors:  Daphne R Mattos; Marcus A Weinman; Xuemei Wan; Cheri P Goodall; Jeffrey D Serrill; Kerry L McPhail; Milan Milovancev; Shay Bracha; Jane E Ishmael
Journal:  Cell Stress Chaperones       Date:  2022-03-04       Impact factor: 3.827

4.  Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer.

Authors:  Chenlian Yang; Zhiwei Zhang; Yutian Zou; Guanfeng Gao; Lingrui Liu; Haifan Xu; Feng Liu
Journal:  Histol Histopathol       Date:  2019-11-19       Impact factor: 2.303

5.  Endoplasmic reticulum stress confers 5-fluorouracil resistance in breast cancer cell via the GRP78/OCT4/lncRNA MIAT/AKT pathway.

Authors:  Xiaoli Yao; Yi Tu; Yulin Xu; Yueyue Guo; Feng Yao; Xinghua Zhang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 6.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

Review 7.  Natural Products Targeting ER Stress, and the Functional Link to Mitochondria.

Authors:  Stefania Martucciello; Milena Masullo; Antonietta Cerulli; Sonia Piacente
Journal:  Int J Mol Sci       Date:  2020-03-11       Impact factor: 5.923

Review 8.  The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias.

Authors:  Alberto M Martelli; Francesca Paganelli; Francesca Chiarini; Camilla Evangelisti; James A McCubrey
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

9.  Cell Surface GRP78 as a Death Receptor and an Anticancer Drug Target.

Authors:  Ruowen Ge; Chieh Kao
Journal:  Cancers (Basel)       Date:  2019-11-13       Impact factor: 6.639

10.  HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.

Authors:  Yong Wu; Qinhao Guo; Xingzhu Ju; Zhixiang Hu; Lingfang Xia; Yu Deng; Ping Zhao; Meng Zhang; Yang Shao; Shenglin Huang; Xianghuo He; Hao Wen; Xiaohua Wu
Journal:  Oncogene       Date:  2021-06-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.